In the SEQC/MAQC-III Consortium data, TFAP2B expression is decreased in stage 4 or metastatic neuroblastomas (Additional file 1: Fig. S5F) and low expression of TFAP2B is associated with worse event-free survival outcomes in non-MYCN amplified neuroblastoma patients (Additional file 1: Fig. S5G). This evidence concerns the gene MYCN and neuroblastoma.